Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8022021 | 0.78 | HDAC6 (0.40) | HDAC6HDAC1LTA4H | |
| SCHEMBL2010864 | 0.74 | HDAC6 (0.40) | HDAC6HDAC1LTA4H | |
| SCHEMBL21357355 | 0.74 | HDAC6 (0.40) | HDAC6HDAC1LTA4H | |
| SCHEMBL4512499 | 0.71 | HDAC6 (0.44) | HDAC6HDAC1LTA4H | |
| SCHEMBL4512503 | 0.71 | HDAC6 (0.44) | HDAC6HDAC1LTA4H | |
| SCHEMBL820304 | 0.69 | HDAC6 (0.38) | HDAC6HDAC1LTA4H | |
| SCHEMBL48336 | 0.69 | ADORA2A (0.47) | HDAC6HDAC1LTA4H | |
| SCHEMBL754082 | 0.69 | ADORA2A (0.47) | HDAC6HDAC1LTA4H | |
| SCHEMBL338773 | 0.69 | HDAC6 (0.52) | HDAC6HDAC1LTA4H | |
| SCHEMBL2182600 | 0.67 | HDAC6 (0.42) | HDAC6HDAC1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4372102-A2 | TARGET REPORTER CONSTRUCTS AND USES THEREOF | RedVault Biosciences, LP (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-3464628-B1 | TARGET REPORTER CONSTRUCTS AND USES THEREOF | REDVAULT BIOSCIENCES LP (US) | 2024-01-31 | — | — | EP | disclosed |
| US-11299769-B2 | Target reporter constructs and uses thereof | REDVAULT BIOSCIENCES, LP (US) | 2022-04-12 | — | — | US | disclosed |
| CN-113528628-A | Systems and methods for clonal replication and amplification of nucleic acid molecules for genomic and therapeutic applications | 雷德沃特生物科学公司 | 2021-10-22 | — | — | CN | disclosed |
| EP-3129505-B1 | METHODS FOR CLONAL REPLICATION AND AMPLIFICATION OF NUCLEIC ACID MOLECULES FOR GENOMIC AND THERAPEUTIC APPLICATIONS | REDVAULT BIOSCIENCES LP (US) | 2021-06-30 | — | — | EP | disclosed |
| CN-112472699-A | Combination methods for improving the therapeutic benefit of bisantrene and derivatives | 种族肿瘤学公司 | 2021-03-12 | — | — | CN | disclosed |
| EP-3464628-A1 | TARGET REPORTER CONSTRUCTS AND USES THEREOF | RedVault Biosciences LP (US) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017214127-A1 | TARGET REPORTER CONSTRUCTS AND USES THEREOF | REDVAULT BIOSCIENCES, LP (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20170349939-A1 | TARGET REPORTER CONSTRUCTS AND USES THEREOF | REDVAULT BIOSCIENCES, LP (US) | 2017-12-07 | — | — | US | disclosed |
| US-20170067097-A1 | SYSTEMS AND METHODS FOR CLONAL REPLICATION AND AMPLIFICATION OF NUCLEIC ACID MOLECULES FOR GENOMIC AND THERAPEUTIC APPLICATIONS | REDVAULT BIOSCIENCES, LP (US) | 2017-03-09 | — | — | US | disclosed |
| EP-1947101-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2008-07-23 | — | — | EP | disclosed |
| US-7351841-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-04-01 | — | — | US | disclosed |
| US-20080027068-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| EP-1845090-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2007-10-17 | — | — | EP | disclosed |
| EP-1819692-A1 | 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2007-08-22 | — | — | EP | disclosed |
| CN-1798739-A | 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators | NISSAN CHEMICAL IND LTD (JP) | 2006-07-05 | — | — | CN | disclosed |
| WO-2006062240-A1 | 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2006-06-15 | — | — | WO | disclosed |
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1636192-A1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004108683-A1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NR2C2, ROR1, NR0B2 | HDAC6 2166/4885HDAC1 1314/4885LTA4H 1449/4885 |
| US-20080027068-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | HDAC6 2404/4885HDAC1 1589/4885LTA4H 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.